



Attorney Ref. 3015/6/US
HDP Ref. 6794-000032/COA

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Ashok Anantanarayan et al.
Serial No: 10/021,780
Filed: December 7, 2001
For: SUBSTITUTED PYRAZOLES AS P38 KINASE INHIBITORS
Group Art Unit: Not known
Examiner: Not known
Attorney Ref: 3015/6/US

February 13, 2002

AMENDMENT A

TO THE COMMISSIONER OF PATENTS AND TRADEMARKS,
SIR/MADAM:

Applicants submit this Amendment A in the above-referenced patent application in response to the January 29, 2002 Notice to File Corrected Application Papers (copy enclosed).

20020213 09:03:00


Amendments to Specification

Please delete lines 5 through 8 on page 1 and substitute with the following:

This application claims priority to U.S. Patent Application No. 09/513,351 (filed February 24, 2000), which, in turn, claims priority to both International Patent Application PCT/US99/26007 (filed on November 17, 1999, and published as International Publication No. WO 00/31063) and U.S. Patent Application No. 09/196,623 (filed November 20, 1998). International Patent Application PCT/US99/26007 claims priority to U.S. Patent Application No. 09/196,623. U.S. Patent Application No. 09/196,623 claims priority to U.S. Patent Application No. 09/083,670 (filed May 22, 1998), which, in turn, claims priority to U.S. Provisional Patent Application No. 60/047,570 (filed May 22, 1997). The text of each of the above-referenced applications is incorporated by reference.

Please insert the following text on a new page at the end of the application (*i.e.*, after the claims):

ABSTRACT



A class of pyrazole derivatives is described for use in treating p38 kinase mediated disorders. Compounds of particular interest are defined by Formula (IA), wherein R^1 , R^2 , R^3 and R^4 are as described in the specification.

Remarks

Consideration on the merits of the above-referenced patent application is requested.

Amendments to the Specification

The specification has been amended by this Amendment A. The amended text is shown in the previous section, and the corresponding amendments are shown in Appendix A.


I. Notice to File Corrected Application Papers Due to Failure to Include an Abstract as Required under 37 C.F.R. §1.72(b)

Applicants received a Notice to File Corrected Application Papers for failure to submit an abstract. Applicants have amended the specification to include an abstract. This is the same language as in the abstract on the cover sheet of the published grandparent PCT. Thus, this amendment is not new matter.

II. Amendment to Properly Claim Priority to Earlier Filed Applications.

In accordance with 37 CFR §1.78 and MPEP §202.01, the beginning of the specification has been amended to identify the patent application to which this patent application is claiming priority.

Respectfully submitted,



David M. Gryte, PTO Reg. No. 41,809
Harness, Dickey & Pierce
7700 Bonhomme, Suite 400
Clayton, Missouri 63105
(314) 726-7500 (tel)
(314) 726-7501 (fax)

Appendix A
Amendments to Specification

The following amendments were made to the specification by Amendment A:


The following changes were made on lines 5 through 8 on page 1:

[This application is related to U.S. Provisional Application Serial No. 60/047,570 filed May 22, 1997 and U.S. Application Serial No. 09/083,670 filed May 22, 1998.]

This application claims priority to U.S. Patent Application No. 09/513,351 (filed February 24, 2000), which, in turn, claims priority to both International Patent Application PCT/US99/26007 (filed on November 17, 1999, and published as International Publication No. WO 00/31063) and U.S. Patent Application No. 09/196,623 (filed November 20, 1998). International Patent Application PCT/US99/26007 claims priority to U.S. Patent Application No. 09/196,623. U.S. Patent Application No. 09/196,623 claims priority to U.S. Patent Application No. 09/083,670 (filed May 22, 1998), which, in turn, claims priority to U.S. Provisional Patent Application No. 60/047,570 (filed May 22, 1997). The text of each of the above-referenced applications is incorporated by reference.

The following new text was inserted on new page 1217 (*i.e.*, at the end of the application):

ABSTRACT



A class of pyrazole derivatives is described for use in treating p38 kinase mediated disorders. Compounds of particular interest are defined by Formula (IA), wherein R^1 , R^2 , R^3 and R^4 are as described in the specification.

200320-032200T

CERTIFICATE OF MAILING

I certify that this **Amendment A** is being deposited with the United States Postal Service as first class mail in an envelope addressed to: **Commissioner for Patents, Washington, D.C. 20231** on **February 13, 2002**.

Lana B. Ekus

DMG/LE